<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00392691</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 37/05</org_study_id>
    <secondary_id>SWS-SAKK-37/05</secondary_id>
    <secondary_id>EU-20648</secondary_id>
    <secondary_id>SPRI-SWS-SAKK-37/05</secondary_id>
    <secondary_id>CDR0000511915</secondary_id>
    <nct_id>NCT00392691</nct_id>
  </id_info>
  <brief_title>Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment</brief_title>
  <official_title>Ibritumomab Tiuxetan and High-Dose Melphalan as Conditioning Regimen Before Autologous Stem Cell Transplantation for Elderly Patients With Lymphoma in Relapse or Resistant to Chemotherapy. A Multicenter Phase I Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy drugs, such as melphalan, before an autologous stem cell
      transplant helps stop the growth of cancer cells, either by killing the cells or by stopping
      them from dividing. Also, monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan
      and rituximab, can find cancer cells and carry cancer-killing substances to them without
      harming normal cells. Chemotherapy and monoclonal antibody therapy also prepares the
      patient's bone marrow for the stem cell transplant. Giving colony-stimulating factors, such
      as G-CSF, and vinorelbine helps stem cells move from the bone marrow to the blood so they can
      be collected and stored. The stem cells are returned to the patient to replace the
      blood-forming cells that were destroyed by the chemotherapy and monoclonal antibody therapy.

      PURPOSE: This phase I trial is studying the side effects and best dose of melphalan when
      given together with yttrium Y 90 ibritumomab tiuxetan and rituximab followed by autologous
      stem cell transplant in treating older patients with non-Hodgkin's lymphoma that has relapsed
      or not responded to previous treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the maximum tolerated dose of high-dose melphalan when given together with
           yttrium Y 90 ibritumomab tiuxetan and rituximab as a conditioning regimen followed by
           vinorelbine ditartrate- and filgrastim (G-CSF)-mobilized autologous stem cell
           transplantation in elderly patients with relapsed or refractory CD20-positive
           non-Hodgkin's lymphoma.

        -  Evaluate the feasibility and safety of this regimen in these patients.

        -  Determine the feasibility of stem cell mobilization with vinorelbine ditartrate in
           patients treated with this regimen.

      OUTLINE: This is a multicenter, dose-escalation study of high-dose melphalan.

        -  Stem cell harvest and mobilization: Patients receive vinorelbine ditartrate IV on day
           -36 and filgrastim (G-CSF) subcutaneously (SC) twice daily on days -33 to -29. Patients
           undergo peripheral blood stem cell harvest on days -29 to -26.

        -  Radioimmunotherapy: Patients receive rituximab IV. Within 4 hours after completion of
           rituximab, patients receive indium In 111 ibritumomab tiuxetan (imaging dose) IV over 10
           minutes on day -25. Patients undergo assessment of biodistribution, imaging, and
           dosimetry on days -25, -22, and optionally on day -20. Patients with acceptable
           biodistribution of indium In 111 ibritumomab tiuxetan receive rituximab IV followed by
           yttrium Y 90 ibritumomab tiuxetan (therapeutic dose) IV over 10 minutes on day -18.

        -  High-dose chemotherapy: Patients receive high-dose melphalan IV on day -1. Cohorts of
           3-6 patients receive escalating doses of high-dose melphalan until the maximum tolerated
           dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6
           patients experience dose-limiting toxicity.

        -  Autologous stem cell transplantation (ASCT): Patients undergo ASCT on day 0. Patients
           receive G-CSF SC beginning on day 5 and continuing until blood counts recover.

      After completion of study treatment, patients are followed for 100 days.

      PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity of high-dose melphalan in combination with yttrium Y 90 ibritumomab tiuxetan</measure>
    <time_frame>within 8 weeks after application of melphalan</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>100 days (+/- 5 days) after reinfusion of stem cells</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event occurrence up to 100 days after transplantation</measure>
    <time_frame>up to 100 days after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission 100 days after transplantation</measure>
    <time_frame>100 days after transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Zevalin, Rituximab, Melphalan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibritumomab tiuxetan</intervention_name>
    <description>185 MBq (5mCi) of 111In-Zevalin will be used for radioimaging. and the dose is 14.8 MBq/kg (0.4 mCi/kg) total body weight of 90Y-Zevalin (max. 1184 MBq or 32 mCi at patients &gt; 80kg) for imaging.</description>
    <arm_group_label>Zevalin, Rituximab, Melphalan</arm_group_label>
    <other_name>ZEVALIN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>250 mg/m2</description>
    <arm_group_label>Zevalin, Rituximab, Melphalan</arm_group_label>
    <other_name>MabThera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Dose level 1: 100 mg/m2
Dose level 2: 140 mg/m2
Dose level 3: 170 mg/m2
Dose level 4: 200 mg/m2</description>
    <arm_group_label>Zevalin, Rituximab, Melphalan</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine tartrate / G-CSF</intervention_name>
    <description>on day 1: 35 mg/m2 day 4-8 (longer if required) G-CSF 5 μg/kg s.c. morning and 5 μg/kg s.c. evening for at least 5 days</description>
    <arm_group_label>Zevalin, Rituximab, Melphalan</arm_group_label>
    <other_name>Navelbine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous hematopoietic stem cell harvesting and transplantation</intervention_name>
    <description>Optimal mobilization usually takes place on day 8. A minimum of 2.5x106 CD34+ cells/kg should be collected (optimal 5x106 CD34+ cells/kg). If not enough CD34+ cells can be collected on day 8, it is recommended to continue with G-CSF until a sufficient collection (a minimum of 2.5x106 CD34+ cells/kg) can be obtained.
Stem cells will be reinfused approximately 24 hours after the melphalan administration. The infusion will be performed with a minimum of 2.5x106 CD34+ cells/kg body weight according to local guidelines. G-CSF (5 μg/kg/d) will be given from day 5 and continued until neutrophils &gt; 0.5x109/l for at least 2 consecutive days.</description>
    <arm_group_label>Zevalin, Rituximab, Melphalan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed non-Hodgkin's lymphoma of any type

          -  CD20-positive disease

          -  Achieved partial or complete response to salvage treatment for relapse or refractory
             disease within the past 10 weeks

          -  Must have an indication for autologous stem cell transplantation

          -  Bone marrow infiltration &lt; 25%

          -  No evidence of CNS involvement

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-1

          -  Bilirubin ≤ 2 times upper limit of normal (ULN)

          -  Alkaline phosphatase ≤ 2 times ULN

          -  AST ≤ 2 times ULN

          -  Creatinine clearance &gt; 50 mL/min

          -  No clinically significant cardiac disease, including any of the following:

               -  Unstable angina pectoris

               -  Significant arrhythmia

               -  Myocardial infarction within the past 3 months

          -  LVEF &gt; 50%

          -  No clinically significant urinary tract obstruction

          -  No clinically significant pulmonary disease

          -  No serious underlying medical condition that would preclude study participation

          -  No other malignancy within the past 5 years except nonmelanoma skin cancer or
             adequately treated in situ cervical cancer

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  At least 30 days since prior participation in another clinical trial

          -  No prior stem cell transplantation

          -  No prior radiolabeled antibodies, including for induction of disease remission

          -  No prior radiotherapy to ≥ 25% of the bone marrow

          -  No concurrent radiotherapy

          -  No other concurrent anticancer drugs

          -  No other concurrent investigational drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Voegeli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kantonsspital Liestal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michele Ghielmini, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>IOSI, Ospedale San Giovanni</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angelika Bischof Delaloye, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Faculté de biologie et de médecine de l' Université de Lausanne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Claraspital AG</name>
      <address>
        <city>Basel</city>
        <zip>4016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital-Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Liestal</name>
      <address>
        <city>Bern</city>
        <zip>CH-3008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Bruderholz</name>
      <address>
        <city>Bruderholz</city>
        <zip>4101</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal Universitaire de Geneve</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2006</study_first_submitted>
  <study_first_submitted_qc>October 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2006</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>Waldenström macroglobulinemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

